APA (7th ed.) Citation

Griffiths, C. E. M., Papp, K. A., Song, M., Miller, M., You, Y., Shen, Y., . . . Blauvelt, A. (2022). Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: Results from VOYAGE 1. Journal of Dermatological Treatment, 33(2), 848. https://doi.org/10.1080/09546634.2020.1782817

Chicago Style (17th ed.) Citation

Griffiths, Christopher E. M., Kim A. Papp, Michael Song, Megan Miller, Yin You, Yaung-Kaung Shen, Chenglong Han, and Andrew Blauvelt. "Continuous Treatment with Guselkumab Maintains Clinical Responses Through 4 Years in Patients with Moderate-to-severe Psoriasis: Results from VOYAGE 1." Journal of Dermatological Treatment 33, no. 2 (2022): 848. https://doi.org/10.1080/09546634.2020.1782817.

MLA (9th ed.) Citation

Griffiths, Christopher E. M., et al. "Continuous Treatment with Guselkumab Maintains Clinical Responses Through 4 Years in Patients with Moderate-to-severe Psoriasis: Results from VOYAGE 1." Journal of Dermatological Treatment, vol. 33, no. 2, 2022, p. 848, https://doi.org/10.1080/09546634.2020.1782817.